PMID- 16461082
OWN - NLM
STAT- MEDLINE
DCOM- 20060331
LR  - 20061115
IS  - 1527-9995 (Electronic)
IS  - 0090-4295 (Linking)
VI  - 67
IP  - 2
DP  - 2006 Feb
TI  - Complexed PSA improves prostate cancer detection: results from a multicenter 
      Japanese clinical trial.
PG  - 328-32
AB  - OBJECTIVES: To compare the distribution of total and complexed prostate-specific 
      antigen (cPSA) in men with and without prostate cancer with another studied 
      population and to ascertain whether cPSA could enhance the detection of prostate 
      cancer in Japanese men. METHODS: A total of 760 men whose serum total PSA (tPSA) 
      values ranged from 1.0 to 100 ng/mL were enrolled. Serum samples for tPSA and 
      cPSA (ADVIA Centaur) were obtained in all cases. The area under the curve was 
      calculated for comparison of the tPSA and cPSA values. We calculated the number 
      of cancers missed and false-positive results at various cutoff values of cPSA 
      compared with the conventional tPSA threshold of 4.0 ng/mL. RESULTS: Prostate 
      cancer was detected in 268 (35.3%) of 760 patients. cPSA was greater than 8.3 
      ng/mL (equivalent to 10.0 ng/mL tPSA) in 46.6% of the men with cancer. The area 
      under the curve for cPSA (0.741) was significantly better than that for tPSA 
      (0.721, P <0.001). At a sensitivity of 85% to 95%, significant differences were 
      found in the corresponding specificity between tPSA and cPSA. cPSA at a 3.0-ng/mL 
      threshold detected an identical number of cancers as a tPSA cutoff of 4.0 ng/mL; 
      however, it decreased the false-positive results by 28 cases. CONCLUSIONS: To our 
      knowledge, this is the first report of the distribution of cPSA in Japanese men 
      using a urologic referral population. cPSA can be an alternative to tPSA as the 
      first screening test. A substantial number of men in Japan with prostate cancer 
      are currently diagnosed with a tPSA value greater than 10.0 ng/mL.
FAU - Okihara, Koji
AU  - Okihara K
AD  - Department of Urology, Kyoto Prefectural University of Medicine, Kyoto, Japan. 
      okiharakoji@hotmail.com
FAU - Ukimura, Osamu
AU  - Ukimura O
FAU - Nakamura, Terukazu
AU  - Nakamura T
FAU - Ushijima, Soh
AU  - Ushijima S
FAU - Mizutani, Yoichi
AU  - Mizutani Y
FAU - Kawauchi, Akihiro
AU  - Kawauchi A
FAU - Naya, Yoshio
AU  - Naya Y
FAU - Kojima, Munekado
AU  - Kojima M
FAU - Miki, Tsuneharu
AU  - Miki T
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Multicenter Study
PL  - United States
TA  - Urology
JT  - Urology
JID - 0366151
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Humans
MH  - Japan
MH  - Male
MH  - Prostate-Specific Antigen/*blood
MH  - Prostatic Neoplasms/*blood/*diagnosis
MH  - Sensitivity and Specificity
EDAT- 2006/02/08 09:00
MHDA- 2006/04/01 09:00
CRDT- 2006/02/08 09:00
PHST- 2005/02/21 00:00 [received]
PHST- 2005/07/18 00:00 [revised]
PHST- 2005/08/12 00:00 [accepted]
PHST- 2006/02/08 09:00 [pubmed]
PHST- 2006/04/01 09:00 [medline]
PHST- 2006/02/08 09:00 [entrez]
AID - S0090-4295(05)01184-2 [pii]
AID - 10.1016/j.urology.2005.08.028 [doi]
PST - ppublish
SO  - Urology. 2006 Feb;67(2):328-32. doi: 10.1016/j.urology.2005.08.028.